Back to discover
Drug

Isoflurophate

In clinical development
ClassAcetylcholinesterase inhibitorEmerging researchIn clinical testing
Also known as DFP, Diisopropoxyphosphoryl fluoride, Diisopropyl fluorophosphonate, Diisopropyl phosphofluoridate+15 more

DFP, Diisopropoxyphosphoryl fluoride, Diisopropyl fluorophosphonate, Diisopropyl phosphofluoridate, Diisopropyl phosphorofluoridate, Diisopropylfluorophosphoric acid ester, Diisopropylphosphofluoridate, Diisopropylphosphorofluoridate, Floropryl, Fluorostigmine, Isopropyl phosphorofluoridate, O,O'-diisopropyl phosphoryl fluoride, fluostigmine, Isofluorphate, Diisopropyl fluorophosphate, Diisopropylfluorophosphate, Fluorodiisopropyl phosphate, Isoflurophosphate, Isopropyl fluophosphate.

RxNorm6027ChEMBLCHEMBL1025ATCS01EB07UNII12UHW9R67N
3
Research papers
Acetylcholinesterase
Primary target
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Pediatric Rat Model of Organophosphate-Induced Refractory Status Epilepticus: Characterization of Long-Term Epileptic Seizure Activity, Neurologic Dysfunction and Neurodegeneration.

Research2024-01-17The Journal of pharmacology and experimental therapeutics

Neuroprotectant Activity of Novel Water-Soluble Synthetic Neurosteroids on Organophosphate Intoxication and Status Epilepticus-Induced Long-Term Neurological Dysfunction, Neurodegeneration, and Neuroinflammation.

Research2024-01-17The Journal of pharmacology and experimental therapeutics

Sex Differences in Organophosphate Model of Benzodiazepine-Refractory Status Epilepticus and Neuronal Damage.

Research2024-01-17The Journal of pharmacology and experimental therapeutics

The Shuttle Effect : Combination Therapy With Deferiprone and Deferasirox in Transfusion-dependent Thalassemia Patients.

Clinical trial2014-07-23Completed · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Isoflurophate
Aliases & brands
DFPDiisopropoxyphosphoryl fluorideDiisopropyl fluorophosphonateDiisopropyl phosphofluoridateDiisopropyl phosphorofluoridateDiisopropylfluorophosphoric acid esterDiisopropylphosphofluoridateDiisopropylphosphorofluoridateFloroprylFluorostigmineIsopropyl phosphorofluoridateO,O'-diisopropyl phosphoryl fluoridefluostigmineIsofluorphateDiisopropyl fluorophosphateDiisopropylfluorophosphateFluorodiisopropyl phosphateIsoflurophosphateIsopropyl fluophosphate
RxNorm CUI
6027
ChEMBL ID
CHEMBL1025
ATC codes
S01EB07
UNII
12UHW9R67N
Primary mechanism
Acetylcholinesterase inhibitor

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Acetylcholinesterase
ACHE · P22303
INHIBITORAcetylcholinesterase inhibitor

Clinical trials

1 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
1
registered trials across all phases
LATEST COMPLETION 2008
1
Late-stage (III+)
1
Completed
PHASE DISTRIBUTIONn = 1
Phase N / A1

Recent completions

Trials that read out recently, adding to the completed evidence base.

The Shuttle Effect : Combination Therapy With Deferiprone and Deferasirox in Transfusion-dependent Thalassemia Patients.

CompletedN/AChina Medical University Hospitaln=132008

Research activity

3 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Major research themes8
Status Epilepticus3Organophosphate Poisoning2Brain Injuries1Epilepsy1Nerve Agents1Neuroprotective Agents1Neurosteroids1Organothiophosphorus Compounds1
Journals, researchers & institutions
Top journals
  • The Journal of pharmacology and experimental therapeutics3
Leading researchers
  • Ramakrishnan S3
  • Reddy DS3
  • Singh T3
  • Wu X3
  • Huber M1
Leading institutions
free-text, unnormalised
  • Texas A&M University School of Medicine2
  • Department of Neuroscience and Experimental Therapeutics and Institute of Pharmacology and Neurotherapeutics1

Related diseases

4 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Related drugs

1 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Midazolam

Studied across 7 of the same disease areas as Isoflurophate in the shared literature.

7 shared diseases2 shared papers
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials